cardiac support News
-
Preclinical results of AdjuCor’s technology to be presented at the upcoming 101st annual meeting of the American Association for Thoracic Surgery (AATS)
In another great achievement for AdjuCor’s ground-breaking new technology within a short period of time, its submitted abstract has been accepted for presentation at the prestigious 101st American Association for Thoracic Surgery (#AATS2021). Prof. Stephan Schueler will be presenting specifics relating to the augmentation technology. Professor Stephan Schueler, Head of Mechanical ...
By AdjuCor GmbH
-
AdjuCor announces first successful in vivo 60-day pre-clinical survival study using its cutting-edge, non-blood-contacting, biventricular cardiac support device.
MUNICH, Germany – October 2nd, 2019: After completing a 60-day pre-clinical study, Professor Stephen Wildhirt, MD, PhD, CEO at AdjuCor, is excited to report on its success. Apart from other achievements, the study confirmed the chronic physiologic acceptance of their non-blood-contacting biventricular cardiac support device by the body. AdjuCor has previously completed a successful 30-day ...
By AdjuCor GmbH
-
AdjuCor’s first international conference presentation has been confirmed – 41st ISHLT Annual Meeting & Scientific Sessions
For the very first time, AdjuCor GmbH's revolutionary new heart-assist technology – BEAT – will take the stage at the prestigious 41st International Society for Heart and Lung Transplantation (#ISHLT2021). Prof. Ulrich Stock will be presenting BEAT’s acute and chronic preclinical results, proudly showcasing this first-in-class technology and how it can assist the failing heart. ...
By AdjuCor GmbH
-
CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device
CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover. Trevor Snyder, PhD, Senior Director, Translational and Clinical Research at CorWave, delivered an oral presentation, “CorWave ...
By CorWave
-
AdjuCor receives further funding for its innovative heart assist device which avoids blood-contact and supports patients with heart failure.
MUNICH, Germany – August 26th, 2019: After reaching a key milestone towards clinical application with a successful 60 day in-vivo study, AdjuCor announces the closure of a new financing round with Hirschvogel Vermögensverwaltung GmbH, a Bavarian Investor who intends to further expand its activity into the medical device arena. Hirschvogel Vermögensverwaltung GmbH announces its ...
By AdjuCor GmbH
-
CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting
CorWave announced today that the latest results of its preclinical Left Ventricular Assist Device (LVAD) development program are presented at the 2020 Virtual OnDemand Conference of the American Society for Artificial Organs (ASAIO), in the Top Abstracts session, available on the ASAIO website1. The presentation, entitled “In Silico, In Vitro and In Vivo Evaluation of the CorWave Membrane ...
By CorWave
-
AdjuCor Raises € 29 Million in Series B Funding Round for its Revolutionary Heart Assist Technology that Completely Avoids Blood Contact
AdjuCor raises € 29 million to enable its next phase of bringing its revolutionary heart assist technology to the severely underserved end-stage heart failure patients. This Series B financing round includes € 25 million from the cardiovascular-focused medical device platform company MitrAssist Holdings Limited accompanied by an additional € 4 million from the returning investor ...
By AdjuCor GmbH
-
AdjuCor enters BMBF supported research collaboration for developing 3D printable biomimetic polymers that mimic properties of the pericardium.
MUNICH, Germany – February 4th, 2020: In the future, novel polymers should make it possible to individually manufacture artificial elastic tissue replacements for pericardium, heart valves or blood vessels. In the PolyKARD project, biomimetic polymers are being developed that can imitate the mechanical properties of pericardial tissue. Using 3D printing and electrospinning, these ...
By AdjuCor GmbH
-
Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™
Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 16-19, 2022 at the Boston Convention ...
-
Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results
Puzzle Medical Devices Inc. is delighted to announce its first-in-human results for the ModulHeart have been presented at the prestigious American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL. Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function ...
-
Reva Medical Announces Final 5 Year Results for It’s Fantom II Coronary Scaffold Study
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications is pleased to announce exceptional 5 Year clinical results from its FANTOM II Study. The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United ...
-
Beacon Biosignals announces partnership with Stratus to advance at-home brain monitoring and machine learning-enabled neurodiagnostics
Beacon Biosignals, which applies AI to EEG to unlock precision medicine for brain conditions, today announced a partnership with Stratus, the nation's leading provider of EEG services, to enable expanded clinical trial service capabilities by leveraging Beacon's machine learning neuroanalytics platform. EEG is standard of care in the clinical diagnosis and management of many neurologic diseases ...
-
First human implant of the Aeson artificial heart in Germany
The implant was performed at Hannover Medical School. Paris, July 26, 2021 – 6:00 pm CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the first implant of its Aeson® bioprosthetic artificial ...
By Carmat
-
Ancora Heart Announces Expansion of U.S. Early Feasibility Study
Santa Clara, Calif.– February 3, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of enrollment in its CorCinch HFrEF Early Feasibility Study (EFS), which is evaluating the AccuCinch® Ventricular Repair System in patients with reduced ejection ...
-
HSC Partners with CardiacSense for medical-grade wearables
CardiacSense is a leading manufacturer of a range of wearable devices for the continuous monitoring of heart arrhythmias and blood pressure HSC signs exclusive Distribution Agreement for Australia & New Zealand for watches & wristbands HomeStay to integrate CardiacSense solutions in HSC’s IoT Platform for assistive technology HomeStay Care Limited (ASX: HSC) ...
By CardiacSense
-
Ancora Heart Receives IDE Approval for CorCinch-HF Pivotal Study of the AccuCinch Ventricular Restoration System
Santa Clara, Calif.– June 30, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in ...
-
Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch Ventricular Restoration System
Santa Clara, Calif.– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the AccuCinch® Ventricular Restoration System. Currently being evaluated in the CORCINCH-HF pivotal clinical trial, the AccuCinch System ...
-
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Professor Daniel Wendt, MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022. Dr. Wendt is an internationally renowned academic cardiac surgeon with over ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you